Curcumin and Boswellia in Inflammatory Disorders: Immune Mechanisms, Bioavailability and Dose Comparability
Nutrients · 25.10.2026 · 18 (21) · 3511
DOI: 10.3390/nu18213511 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 25.10.2026. Verfasst von Sigrun Chrubasik-Hausmann und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Forensic Medicine, Faculty of Medicine and University Hospital, University of Freiburg, Albertstr. 9, 79104 Freiburg, Germany. Hauptthemen laut MEDLINE: Curcumin, Boswellia, Inflammation, Anti-Inflammatory Agents. Die Arbeit nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Curcumin and Boswellia preparations have been investigated for anti-inflammatory and immunomodulatory effects, but clinical translation is complicated by differences in composition, formulation and exposure. This narrative review examines mechanisms, pharmacokinetics and clinical evidence across immune-mediated, degeneration-associated and acute systemic inflammatory disorders, emphasizing dose comparability.
Methods
Literature was identified through iterative PubMed searches and reference list screening, prioritizing recent systematic reviews and meta-analyses and selected primary clinical and pharmacokinetic studies. Experimental pathway effects, human biomarker changes and patient-relevant outcomes were evaluated separately.
Results
Clinical findings suggest potential adjunctive symptomatic benefits, with a comparatively larger evidence base in knee osteoarthritis; findings in other indications remain heterogeneous, inconsistent or limited. Differences in active constituents, delivery technology and administered doses restrict comparisons across preparations. Higher systemic exposure does not by itself establish greater clinical efficacy, and neither pharmacokinetic bioequivalence nor clinically equivalent doses have generally been established across formulations. Local gastrointestinal effects and tissue distribution may also contribute to clinical outcomes. Interpretation is further constrained by small trials, overlapping evidence sources and reported industry relationships. Safety considerations include idiosyncratic liver injury associated with turmeric/curcumin products and potential drug interactions.
Conclusions
Curcumin and Boswellia preparations show potential as adjunctive interventions, but formulation heterogeneity and limitations of the clinical evidence preclude general assumptions of interchangeability or clinical superiority based on increased bioavailability. Future research should prioritize formulation-specific human pharmacokinetics, dose-finding and adequately powered, independently replicated clinical trials, including direct comparisons where appropriate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Forensic Medicine, Faculty of Medicine and University Hospital, University of Freiburg, Albertstr. 9, 79104 Freiburg, Germany.
ORCID-Profile: Sigrun Chrubasik-Hausmann
Zitieren
APA
Chrubasik-Hausmann, S., & Vlachojannis, J. (2026). Curcumin and Boswellia in Inflammatory Disorders: Immune Mechanisms, Bioavailability and Dose Comparability. Nutrients, 18(21), 3511. https://doi.org/10.3390/nu18213511
Vancouver
Chrubasik-Hausmann S, Vlachojannis J. Curcumin and Boswellia in Inflammatory Disorders: Immune Mechanisms, Bioavailability and Dose Comparability. Nutrients. 2026;18(21):3511. doi:10.3390/nu18213511
BibTeX
@article{ChrubasikHausmann2026,
author = {Chrubasik-Hausmann, Sigrun and Vlachojannis, Julia},
title = {Curcumin and Boswellia in Inflammatory Disorders: Immune Mechanisms, Bioavailability and Dose Comparability},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {21},
pages = {3511},
doi = {10.3390/nu18213511}
}
EUVIMED